{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:53:14Z","timestamp":1793033594611,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009109","name":"Pharmaceuticals Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007659","name":"Bayer US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jval.2025.03.007","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:55:52Z","timestamp":1744174552000},"page":"866-874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Health Inequality Impact of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer in the United States: A Distributional Cost-Effectiveness Analysis"],"prefix":"10.1016","volume":"28","author":[{"given":"Jeroen P.","family":"Jansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Brewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Flottemesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie Partridge","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jval.2025.03.007_bib1","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.molonc.2014.10.009","article-title":"Bringing in health technology assessment and cost-effectiveness considerations at an early stage of drug development","volume":"9","author":"J\u00f6nsson","year":"2015","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.jval.2025.03.007_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jval.2018.08.010","article-title":"Identifying the need for good practices in health technology assessment: summary of the ISPOR HTA council working group report on good practices in HTA","volume":"22","author":"Kristensen","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2025.03.007_bib4","doi-asserted-by":"crossref","DOI":"10.3402\/gha.v8.27106","article-title":"Inequalities in health: definitions, concepts, and theories","volume":"8","author":"Arcaya","year":"2015","journal-title":"Glob Health Action"},{"issue":"3","key":"10.1016\/j.jval.2025.03.007_bib5","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.jval.2025.03.007_bib6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN guidelines\u00ae insights: prostate cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"10.1016\/j.jval.2025.03.007_bib7","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"issue":"27","key":"10.1016\/j.jval.2025.03.007_bib8","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.jval.2025.03.007_bib9","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","article-title":"Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jval.2025.03.007_bib10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41391-020-00310-3","article-title":"Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors","volume":"24","author":"Saad","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.jval.2025.03.007_bib11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"issue":"10","key":"10.1016\/j.jval.2025.03.007_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11934-017-0724-5","article-title":"African-American prostate cancer disparities","volume":"18","author":"Smith","year":"2017","journal-title":"Curr Urol Rep"},{"issue":"3","key":"10.1016\/j.jval.2025.03.007_bib13","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/cam4.1885","article-title":"Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients","volume":"8","author":"Panigrahi","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.jval.2025.03.007_bib14","article-title":"NUBEQA (darolutamide) tablets, for oral use: US prescribing information","year":"2019","journal-title":"Approval"},{"issue":"13","key":"10.1016\/j.jval.2025.03.007_bib15","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jval.2025.03.007_bib16","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi","year":"2020","journal-title":"N Engl J Med"},{"issue":"40","key":"10.1016\/j.jval.2025.03.007_bib19","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.2217\/fon-2022-0943","article-title":"Efficacy and safety of darolutamide in Black\/African-American patients from the phase III ARAMIS study","volume":"18","author":"Shore","year":"2022","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.jval.2025.03.007_bib20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jval.2023.11.001","article-title":"The health inequality impact of a new cancer therapy given treatment and disease characteristics","volume":"27","author":"Jansen","year":"2024","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2025.03.007_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/0272989X15583266","article-title":"Distributional cost-effectiveness analysis: a tutorial","volume":"36","author":"Asaria","year":"2016","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.jval.2025.03.007_bib22","series-title":"Distributional Cost-Effectiveness Analysis Quantifying Health Equity Impacts and Trade-Offs: Quantifying Health Equity Impacts and Trade-Offs","author":"Cookson","year":"2020"},{"issue":"2","key":"10.1016\/j.jval.2025.03.007_bib23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jval.2016.11.027","article-title":"Using cost-effectiveness analysis to address health equity concerns","volume":"20","author":"Cookson","year":"2017","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2025.03.007_bib24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40273-022-01131-z","article-title":"Assessments of the value of new interventions should include health equity impact","volume":"40","author":"Jansen","year":"2022","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"10.1016\/j.jval.2025.03.007_bib25","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.jval.2023.08.010","article-title":"The health inequality impact of liquid biopsy to inform first-line treatment of advanced non-small cell lung cancer: a distributional cost-effectiveness analysis","volume":"26","author":"Jansen","year":"2023","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jval.2025.03.007_bib26","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jval.2025.03.007_bib27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/0022-0531(70)90039-6","article-title":"On the measurement of inequality","volume":"2","author":"Atkinson","year":"1970","journal-title":"J Econ Theor"},{"issue":"6","key":"10.1016\/j.jval.2025.03.007_bib28","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.3390\/ijerph19063697","article-title":"Summary measures of health inequality: a review of existing measures and their application","volume":"19","author":"Schlotheuber","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"10.1016\/j.jval.2025.03.007_bib29","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jval.2019.03.006","article-title":"Aggregate distributional cost-effectiveness analysis of health technologies","volume":"22","author":"Love-Koh","year":"2019","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jval.2025.03.007_bib31","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jval.2023.06.015","article-title":"Estimating the US baseline distribution of health inequalities across race, ethnicity, and geography for equity-informative cost-effectiveness analysis","volume":"26","author":"Kowal","year":"2023","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jval.2025.03.007_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139440","article-title":"Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model","volume":"10","author":"Scher","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jval.2025.03.007_bib34","article-title":"Antiandrogen therapies for nonmetastatic castration-resistant prostate cancer: effectiveness and value","author":"Rind","year":"2018","journal-title":"Institute for Clinical and Economic Review"},{"issue":"7","key":"10.1016\/j.jval.2025.03.007_bib36","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jamaoncol.2019.0826","article-title":"Association of black race with prostate cancer-specific and other-cause mortality","volume":"5","author":"Dess","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.jval.2025.03.007_bib37","first-page":"166","article-title":"Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer","volume":"27","author":"Appukkuttan","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.jval.2025.03.007_bib41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/M20-1392","article-title":"A health opportunity cost threshold for cost-effectiveness analysis in the United States","volume":"174","author":"Vanness","year":"2021","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.jval.2025.03.007_bib42","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jval.2022.08.010","article-title":"The impact of funding inpatient treatments for COVID-19 on health equity in the United States: a distributional cost-effectiveness analysis","volume":"26","author":"Kowal","year":"2023","journal-title":"Value Health"},{"issue":"15_suppl","key":"10.1016\/j.jval.2025.03.007_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.5583","article-title":"Cost-effectiveness of novel antiandrogens (AAs) for treatment of nonmetastatic castrate-resistant prostate cancer (nmCRPC)","volume":"38","author":"Riaz","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jval.2025.03.007_bib44","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41391-021-00395-4","article-title":"Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis","volume":"25","author":"Wenzel","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"10.1016\/j.jval.2025.03.007_bib45","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s40273-021-01075-w","article-title":"Why the gap in evaluating the social constructs and the value of medicines?","volume":"39","author":"McRae","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.jval.2025.03.007_bib46","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1037\/hea0000242","article-title":"Understanding associations among race, socioeconomic status, and health: patterns and prospects","volume":"35","author":"Williams","year":"2016","journal-title":"Health Psychol"},{"issue":"1","key":"10.1016\/j.jval.2025.03.007_bib47","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.jval.2025.03.007_bib48","first-page":"221","article-title":"A perfect storm: how tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change","volume":"65","author":"Daly","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.jval.2025.03.007_bib49","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/GIM.0b013e3182091ba4","article-title":"Underutilization of BRCA1\/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk","volume":"13","author":"Levy","year":"2011","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.jval.2025.03.007_bib50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1300\/J077v24n03_02","article-title":"Understanding the breast cancer experience of Latina women","volume":"24","author":"Ashing-Giwa","year":"2006","journal-title":"J Psychosoc Oncol"},{"issue":"3","key":"10.1016\/j.jval.2025.03.007_bib51","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12609-018-0277-8","article-title":"Breast cancer disparities among women in underserved communities in the USA","volume":"10","author":"Thompson","year":"2018","journal-title":"Curr Breast Cancer Rep"},{"issue":"21","key":"10.1016\/j.jval.2025.03.007_bib52","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1002\/cncr.30205","article-title":"National sociodemographic disparities in the treatment of high-risk prostate cancer: do academic cancer centers perform better than community cancer centers?","volume":"122","author":"Mahal","year":"2016","journal-title":"Cancer"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525001238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525001238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T22:46:33Z","timestamp":1753310793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301525001238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1098301525001238"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2025.03.007","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Health Inequality Impact of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer in the United States: A Distributional Cost-Effectiveness Analysis","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2025.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}